METHOD FOR TREATING OBESITY
The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
1 - 17 . (canceled)
18 . A method of promoting weight loss in a mammal comprising:
identifying a mammal in need of such weight loss; and
administering to said mammal at least one compound that enhances the activity of norepinephrine and/or dopamine selected from the group consisting of bupropion, atomoxetine, and reboxetine, and at least one weight-loss promoting anticonvulsant wherein said anticonvulsant is of formula (III):
wherein R 1 is hydrogen or a halogen atom, R 2 and R 3 are the same or different and are each hydrogen or an alkyl having 1 to 3 carbon atoms, and one of X and Y is a carbon atom and another is a nitrogen atom, provided that the group —CH 2 SO 2 NR 2 R 3 is bonded to the carbon atom of either of X and Y, or an alkali metal salt thereof.
19 . The method of claim 18 , wherein said anticonvulsant is zonisamide.
20 . The method of claim 18 , wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.
21 . The method of claim 18 , wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered separately.
22 . The method of claim 18 , wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered concurrently.